의약품부작용보고원시자료(KIDS-KD)를 활용한 baricitinib 및 tocilizumab의 이상사례 분석 및 실마리정보 검색: COVID-19 치료에 사용 시 주의해야 할 이상사례

• Published in: Yaghag-hoi-ji pp. 49 - 57
• Main Authors: 허지영, 신주영
• Format: Journal Article
• Language: Korean
• Published: 대한약학회 01.04.2022
• Subjects: 약학
• ISSN: 0377-9556; 2383-9457
• DOI: 10.17480/psk.2022.66.2.49

Research shows that some severe COVID-19 patients exhibit an excessive inflammatory response with persistentfever; therefore, the drugs that inhibit one or more components of the pro-inflammatory cascade are administered to prevent theworsening of the condition of such patients. According to current updated COVID-19 guidelines, baricitinib and tocilizumab couldbe administered in COVID-19 patients in certain circumstances. To confirm the safety of these drugs, we analyzed the frequencyof the adverse events and detected signals using KIDS-KD. We defined the signals by proportional reporting ratios (PRR),reporting odds ratios (ROR), and information components (IC). “Respiratory system disease” was frequently reported, with bothbaricitinib (17 cases, 15.0%) and tocilizumab (40 cases, 10.6%). It was also detected as a signal with baricitinib but not withtocilizumab. As the symptoms of COVID-19 are mainly related to the respiratory system, close monitoring is necessary for thesepatients. In relation to the risk of infection with tocilizumab, leucopenia (18 cases, 4.7%) and granulocytopenia (7 cases, 1.8%)were reported, and leucopenia was detected as a signal. With baricitinib, pyelonephritis was detected as a signal; however, noprior research that supports this finding exists. We expect this study to provide basic data on the safety of administeringbaricitinib and tocilizumab for COVID-19 patients in certain circumstances. KCI Citation Count: 0